CV Therapeutics, Inc.
CV Therapeutics, Inc. is a biopharmaceutical company focused primarily on the discovery, development and commercialization of new small molecule drugs for the treatment of cardiovascular diseases. The Company applies advances in molecular biology and genetics to identify mechanisms of cardiovascular diseases and targets for drug discovery. It promotes Ranexa (ranolazine extended-release tablets), a small molecule drug that inhibits the late sodium current at therapeutic levels and has antianginal and anti-ischemic effects that do not depend upon reductions in heart rate or blood pressure. In addition to its marketed products, the Company is developing other drug candidates, including regadenoson, a selective application to application (A2A)-adenosine receptor agonist, for potential use as a pharmacologic agent in myocardial perfusion imaging studies.
查看其它語言版本
新聞
週五亞洲各股市在交易時段波動較大，收市漲跌互見。日本日經225指數攀升1.5%，韓國Kospi指數漲0.8%，中國滬市成分指數下跌1.8%，香港恆生指數跌0.7%。在美國政府將增持大塊花旗集團股份的消息出台後，週一東京股市下跌逾3%，韓國股市也受市場日益加深的對金融市場的擔憂以及韓元疲軟的影響，今天開盤走低。
###
50,254 公司背景瀏覽
- 本頁瀏覽人次: (過去7日: 16) (過去30日: 142) (自發布以來: 8979)
